Related Experiment Video

Updated: Aug 3, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis

A M Gotto1, S J Boccuzzi, J R Cook

  • 1Weill Medical College of Cornell University, New York, New York 10021, USA.

The American Journal of Cardiology
|November 25, 2000
PubMed

Insights

Lovastatin treatment significantly reduced cardiovascular hospitalizations and procedures by 29%, extending the time to first event. This cholesterol-lowering drug offers a 11% cost offset, reducing healthcare resource utilization for coronary disease.

Area of Science:

  • Cardiovascular Medicine
  • Health Economics
  • Pharmacoeconomics

Background:

  • Coronary heart disease necessitates significant healthcare resource utilization.
  • Statins, like lovastatin, are crucial in managing hypercholesterolemia and preventing cardiovascular events.
  • Cost-effectiveness analyses are vital for evaluating the economic impact of cardiovascular therapies.

Purpose of the Study:

  • To conduct a cost-consequences analysis of lovastatin treatment versus cardiovascular hospitalizations and procedures.
  • To quantify the reduction in cardiovascular-related resource utilization and direct medical costs associated with lovastatin therapy.

Main Methods:

  • A cost-consequences analysis was performed using data from the Air Force/Texas Coronary Atherosclerosis Prevention Study.
  • Costs included lovastatin treatment (drug price, monitoring, adverse events) and actual rates of cardiovascular hospitalizations and procedures.
  • Statistical analysis compared outcomes between lovastatin treatment and control groups.

Main Results:

  • Lovastatin treatment cost approximately $4,654/patient.
  • Significantly reduced cumulative cardiovascular hospitalizations and procedures by 29% (p=0.002).
  • Reduced cardiovascular hospital days by 26% (p=0.025) and yielded a $524 (11%) cost offset over 5.2 years.

Conclusions:

  • Lovastatin therapy significantly decreases cardiovascular-related hospitalizations, procedures, and associated costs.
  • The drug demonstrates meaningful reductions in resource utilization for patients with coronary disease.
  • Lovastatin provides a substantial cost offset, highlighting its economic benefits in cardiovascular disease management.

More Related Videos

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...